Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT

Novo Nordisk CEO said the Danish weight-loss drugmaker is open to upgrading its New York listing to raise its profile in the U.S. The comments signal potential efforts to broaden U.S. investor visibility and improve access to the company’s largest healthcare capital market, though no transaction or timeline was disclosed.